Global Tissue Diagnostics Market Research and Forecast, 2018-2023
|発行||Orion Market Research Pvt Ltd||商品コード||425938|
|世界の細胞診断市場の分析 Global Tissue Diagnostics Market Research and Forecast, 2018-2023|
|出版日: 2018年03月06日||ページ情報: 英文||
Tissue Diagnostics Market is expected to grow with a CAGR 7.7% during 2018-2023. Need for more accurate diagnosis in cases of cancer has resulted in development more advanced diagnostic technologies such as tissue diagnostics. Cancer is a fatal disease and it is prevalent across the globe with huge economic burden in emerging and low-middle income group countries. It has considerable presence in developed and developing economies such as US, UK, Spain, China, India and Korea. Tissue diagnosis includes Haematoxylin & Eosin (H&E) Stain, Immunohistochemistry (IHC) Test, Fluorescent in Situ Hybridization (FISH) Test, Silver in Situ Hybridization (SISH) Test, Pathology and other stain tests. These diagnostic services are widely available and due to technological advancement, innovation and efficient results these diagnostic devices are in huge demand.
Tissue diagnostics market on the basis of geographical regions is analysed as North America, Europe, APAC, and Rest of the world. Asia Pacific generates highest revenues across the globe due to high prevalence of cancer. APAC region such as China, India, Japan and Korea are the key markets and expected to improve upon their existing diagnostic technologies. Improved healthcare spending, infrastructure and favourable government policies are the key factors which are expected to drive the APAC market. The report includes detailed market overview, market determinants, company profiling, sector analysis, market segmentation, geographical analysis, pipeline analysis, strategic recommendations, key company analysis, gap analysis, key findings, market estimations, market insights, analyst insights and predictive analysis of the market.
The report also covers various factors that influence the market such as the government regulations, drug and device laws and regulations, regulations on clinical trials and government policies. The report also covers parametric analysis, historical analysis and tissue diagnosis which includes various test such as Haematoxylin and silver in situ hybridization test. Global tissue diagnostic market is segmented on the basis of technology, diagnosis, product, end user and geography.
The key players of global tissue diagnostic market includes Abbott Laboratories, Roche Holdings AG, Biogenex Laboratories, Bio SB, Agilent Technologies Cell Signaling Technology, Danaher Corporation, Sigma-Aldrich, Thermo Fisher Scientific, Qiagen, Becton Dickinson & company, Alere, Diagenic, Stryker, Biomeriux, Promethius Laboratories, Life Technologies, GE healthcare, Philips, Siemens, Johnson & Johnson, Quest Diagnostic, Axxin, Caris Life Sciences, Singulux, Teco Diagnostic, Ribomed, Signal Genetics and so on.
Global Tissue Diagnostics Market by Technology
Global Tissue Diagnostics Market by Disease
Global Tissue Diagnostics Market by Product
Global Tissue Diagnostics Market by End Users
The market study of tissue diagnostic market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analysing various regional players, regional tax laws and policies, consumer behaviour and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases
Whitepapers, research-papers and news blogs
Company websites and their product catalogue.
Supplier Websites such as Alibaba, amazon for pricing analysis.
The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
The Report covers:
Comprehensive research methodology of Global Tissue Diagnostics Market.
This report also includes detailed and extensive market overview with Analyst insights & key market trends.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the Global Tissue Diagnostics Market.
Insights about market determinants which are stimulating the Global Tissue Diagnostics Market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
1 REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2 MARKET OVERVIEW AND INSIGHTS
2.1. GAP ANALYSIS
2.2. HISTORICAL ANALYSIS
2.3. PARAMETRIC ANALYSIS
2.3.1. RISING INCIDENCE AND PREVALENCE RATE OF CANCER
2.3.2. EPIDEMIC OF NEURO-DEGENERATIVE DISEASES
2.3.3. RISING DIAGNOSTIC CENTERS ACROSS GEOGRAPHIES
2.3.4. RISING LABORATORIES ACROSS GEOGRAPHIES
2.3.5. HOSPITAL AND RESEARCH CENTER ON RISE
2.4. ANALYST INSIGHT
2.4.1. KEY FINDINGS AND CURRENT TRENDS
2.5.1. REGULATIONS ON CLINICAL TRIALS
18.104.22.168. UNITED STATES
22.214.171.124. EUROPEAN UNION
2.5.2. DRUG AND DEVICE REGULATIONS
126.96.36.199. UNITED STATES
188.8.131.52. EUROPEAN UNION
3 MARKET DETERMINANT
3.1.1. RISE IN PERSONALIZED HEALTHCARE
3.1.2. RISING IN-VITRO DIAGNOSTICS ENABLES TISSUE DIAGNOSTIC MARKET TO GROW SIGNIFICANTLY
3.1.3. RISE IN CANCER INCIDENCE & PREVALENCE
3.1.4. FDA APPROVALS ARE ON RISE AND MAY ATTRACT OTHER BIG PLAYERS TO ENTER INTO THE TISSUE DAIGNOSTIC MARKET
3.1.5. RISE IN ADOPTION OF CANCER DIAGNOSTICS AND TREATMENT
3.1.6. TECHNOLOGICAL ADVANCEMENT IN TISSUE DIAGNOSTIC
3.1.7. DEVELOPMENT IN PROTEOMICS AND GENOMICS
3.1.8. INNOVATION IN DIAGNOSTIC AND TREATMENT
3.1.9. FAVORABLE GOVERNMENT POLICIES AND REGULATIONS
3.1.10. RESEARCH & DEVELOPMENT TO DRIVE THE TISSUE DIAGNOSTIC MARKET
3.2.1. HIGH COST OF DIAGNOSIS & TREATMENT
3.2.2. STRINGENT GOVERNMENT REGULATIONS
3.3.1. COST SAVING FOR LABORATORIES DUE TO EFFICIENT TISSUE DIAGNOSTIC DEVICES
3.3.2. ADOPTION OF LAB AUTOMATION TECHNOLOGY IN TISSUE DIAGNOSTIC
3.3.3. UNTAPPED APAC REGION IS FULL OF OPPORTUNITY FOR GLOBAL TISSUE DIAGNOSTIC MARKET
3.3.4. CLINICAL TRIALS ARE PREDICTED TO INCREASE IN NEXT FEW YEARS
3.3.5. COLLABORATION AND PARTNERSHIP IN TISSUE DAIGNOSTIC MARKET
4 IN VITRO DIAGNOSTICS MARKET ANALYSIS
5 MARKET SEGMENTATION
5.1. BY TECHNOLOGY
5.1.2. IN SITU HYBRIDIZATION
5.1.3. DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT
5.1.4. SPECIAL STAINING
5.1.5. HEMATOXYLIN & EOSIN (H&E) STAIN
5.2. BY DISEASES
5.2.1. BREAST CANCER
5.2.2. GASTRIC CANCER
5.2.4. PROSTATE CANCER
5.2.5. NON-SMALL CELL LUNG CARCINOMA
5.3. BY PRODUCT
184.108.40.206. SLIDE STAINING SYSTEMS
220.127.116.11. TISSUE PROCESSING SYSTEMS
18.104.22.168. OTHER PRODUCTS MARKET
5.4. BY END USER
5.4.3. RESEARCH INSTITUTES
5.4.5. OTHER RESEARCH
6 COMPETETIVE LANDSCAPE
6.1. MARKET SHARE ANAYSIS
6.2. KEY COMPANY ANALYSIS
7 REGIONAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.2.1. WESTERN EUROPE
7.2.2. REST OF EUROPE
7.3. ASIA PACIFIC
7.3.4. REST OF ASIA PACIFIC
7.4. REST OF THE WORLD
8 COMPANY PROFILES
8.1. AGILENT TECHNOLOGIES
8.4. BECTON DICKINSON & COMPANY
8.5. BIO SB.
8.7. BIOGENEX LABORATORIES
8.9. CARIS LIFE SCIENCES
8.10. CELL SIGNALLING TECHNOLOGY, INC.
8.11. DANAHER CORPORATION.
8.14. GE HEALTHCARE
8.15. GRIFOLS DIAGNOSTIC SOLUTIONS INC
8.16. JOHNSON & JOHNSON
8.19. PROMETHEUS LABORATORIES
8.21. QUEST DIAGNOSTIC
8.23. ROCHE HOLDINGS AG
8.25. SIGNAL GENETICS
8.28. TECO DIAGNOSTICS
8.29. TRINITY BIOTECH